The high costs associated with preimplantation genetic diagnosis (PGD) procedures can hamper the market growth. PGD involves complex laboratory procedures that are resource and labor intensive. It starts with in- vitro fertilization where multiple embryos are conceived and developed in laboratory conditions. Further, each embryo undergoes genetic testing to detect any abnormalities or inherited disorders. The process requires specialized equipment, trained personnel and advanced genetic testing techniques. All of these factors contribute to the overall high costs of procedure. On an average, a single PGD cycle costs between US$ 10,000 to US$ 15,000 in most countries, which is significantly higher as compared to a normal IVF cycle. Multiple cycles may be required to obtain healthy embryos, thus, increasing procedure costs. The out-of-pocket expenses have to be borne by patients as most health insurance policies do not cover PGD. This pricing puts the procedure out of reach for many aspiring parents from low- and middle-income groups globally. In 2020, according to the data from the United Kingdom National Health Services, nearly 60% of IVF cycles were self-funded due to lack of insurance coverage.
Market Opportunities: Emerging markets in Asia Pacific and Latin America
The emerging markets in Asia Pacific and Latin America offer tremendous growth opportunities for the global preimplantation genetic diagnosis market. These regions are witnessing rapid economic expansion coupled with rising healthcare investments that increases access to advanced infertility treatments. Countries like China, India, Brazil and Mexico have a very young population structure with growing middle class who can afford expensive procedures like IVF and PGD. As per data from United Nations Population Fund, over 60% of Latin America's population and almost 65% of Asia Pacific's population is now under the age of 30. This young demography boosts demand for advanced fertility services to build families. Social trends like women pursuing careers before childbearing boosts the need for PGD to select healthy embryos. Furthermore, governments in emerging nations recognize the social and economic burden of genetic diseases and birth defects. These are working to strengthen newborn screening programs and promoting preventive healthcare. For instance, India's 'New-born screening initiative' aims to test over 5 million babies annually for treatable genetic conditions by 2025, according to the Nation's Health Ministry. Government of Brazil launched the 'Mother Baby' program in 2021 to provide subsidized NIPT (Non-invasive prenatal tests) and ART procedures for at-risk pregnancies as per its health ministry report.
Preimplantation Genetic Diagnosis Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients